Mark Purcell
Stock Analyst at Morgan Stanley
(1.32)
# 3,679
Out of 5,115 analysts
6
Total ratings
66.67%
Success rate
-6.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $47.04 | +23.30% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $148.68 | -23.33% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $51.60 | -14.73% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $92.77 | -8.38% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $59.43 | +101.92% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $47.04
Upside: +23.30%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $148.68
Upside: -23.33%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $51.60
Upside: -14.73%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $92.77
Upside: -8.38%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $59.43
Upside: +101.92%